摘要
目的:研究重组人干扰素α2b栓及保妇康栓对慢性子宫颈炎并发高危型人乳头瘤病毒(HPV)感染患者的疗效及免疫炎症反应的影响。方法:选择2020年4月—2022年4月成武县人民医院收治的83例慢性子宫颈炎并发高危型HPV感染患者作为研究对象,将患者根据入院就医先后次序差异分为联合组(41例)与对照组(42例)。对照组给予重组人干扰素α2b栓治疗,联合组在对照组基础上给予保妇康栓治疗。比较两组临床疗效,治疗前后HPV病毒载量、子宫颈炎评分、血清炎症因子及T淋巴细胞亚群,不良反应发生情况。结果:联合组总有效率高于对照组,差异有统计学意义(P<0.05)。联合组治疗后HPV病毒载量、子宫颈炎评分低于对照组,差异有统计学意义(P<0.05)。治疗后,两组血清肿瘤坏死因子-α(TNF-α)、白细胞介素-2(IL-2)、白细胞介素-6(IL-6)、CD8~+较治疗前降低,且联合组低于对照组,两组CD3~+、CD4~+、CD4~+/CD8~+较治疗前提高,且联合组高于对照组,差异有统计学意义(P<0.05)。联合组不良反应发生率为17.07%,与对照组的9.52%比较,差异无统计学意义(P>0.05)。结论:重组人干扰素α2b栓及保妇康栓对慢性子宫颈炎并发高危型HPV感染患者的疗效较佳,可改善免疫炎症反应。
Objective:To study the influence of Recombinant Human Interferonα2b Suppository and Baofukang Suppository on efficacy and immune inflammatory response of patients with chronic cervicitis complicated with high-risk Human papilloma virus(HPV)infection.Method:A total of 83 patients with chronic cervicitis complicated with high-risk HPV infection who admitted to Chengwu County People's Hospital from April 2020 to April 2022 were selected as the study objects,the patients were divided into the combination group(41 cases)and the control group(42 cases)according to the difference in the order of hospitalization.The control group was treated with Recombinant Human Interferonα2b Suppository,the combination group was treated with Baofukang Suppository on the basis of the control group.The clinical efficacy,HPV viral load and cervicitis score,serum inflammatory factor levels and T lymphocyte subsets index levels before and after treatment,adverse reactions were compared between two groups.Result:The total effective rate of the combination group was higher than that in the control group,the difference was statistically significant(P<0.05).The HPV viral load and cervicitis score in combination group after treatment were lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,the levels of serum tumor necrosis factor-α(TNF-α),interleukin-2(IL-2),interleukin-6(IL-6)and CD8+in two groups were lower than those before treatment,and those in the combination group were lower than those in the control group,the levels of CD3+,+CD4 and CD4+/CD8+in two groups were higher than those before treatment,and those in the combination group were higher than those in the control group,the differences were statistically significant(P<0.05).The incidence of adverse reactions in the combination group was 17.07%,compared with 9.52%in the control group,the difference was not statistically significant(P>0.05).Conclusion:Recombinant Human Interferonα2b Suppository and Baofukang Suppository have
作者
何艳
HE Yan(Chengwu County People's Hospital,Chengwu 274200,China)
出处
《中外医学研究》
2023年第33期133-136,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
慢性子宫颈炎
人乳头瘤病毒
重组人干扰素α2b栓
保妇康栓
Chronic cervicitis
Human papilloma virus
Recombinant
Human
Interferonα2b
Suppository
Baofukang
Suppository
